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Objective: Elevated liver function tests (LFTs) are common in adult Turner syndrome (TS) patients. Data regarding children and 
adolescents are lacking. To investigate the prevalence of abnormal LFTs in children and adolescents with TS during several years of 
observation; to evaluate the potential impact of increased body mass index (BMI) and sex hormone replacement therapy (HRT) on LFTs. 
Methods: The analysis included 100 girls with TS, aged 4-16 years, all of whom were receiving recombinant human growth hormone 
therapy. A longitudinal study was conducted which included 81 patients.
Results: Mean BMI-standard deviation (SD) score of the subjects was 0.63 (SD: 1.53). Forty-four were being treated with HRT. Elevated 
LFTs were found in 34% of the patients overall (32% not receiving HRT vs 36% on HRT). The relative risk of increased LFTs was not 
higher in obese vs normal weight [odds ratio (OR): 0.2; 95% confidence interval (CI): 0.1-0.36, p=0.38 vs OR: 0.16; 95% CI: 0.08-
0.3, p=0.1]. HRT did not increase the risk of abnormal LFTs activity (OR: 0.8; 95% CI: 0.5-1.2, p=0.37 vs OR: 0.7; 95% CI: 0.4-1.1, 
p=0.27). During the follow-up period (mean±SD=4.31±0.82 years), no patient developed overt liver disease. There was no significant 
increase nor decrease of abnormal LFT frequency in the subsequent years of follow up. 
Conclusion: Constantly elevated LFTs in TS are common in children and adolescents with TS. However the causes and clinical significance 
remain unclear. This study suggests that obesity and HRT do not increase the risk of elevated LFTs. 
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Introduction
Turner syndrome (TS) affects approximately 1 per 2500 
live female births and is one of the most common 
chromosomal aberration in females (1,2). It is caused 
by a partial or complete X chromosome monosomy. 
Conditions often seen in TS include: short stature, 
ovarian dysgenesis, dysmorphic features and endocrine 
disturbances such as diabetes mellitus and thyroiditis. 
Liver involvement indicated by abnormal liver function 
tests (LFT) seems to be frequent in adult TS patients, 
with a prevalence of 20 to 80% (3,4,5,6). Data on 
children and adolescents are lacking. The causes and 
clinical significance of this phenomenon are unclear. 
Nevertheless, overt liver diseases are also more common 
in TS patients than in the general population. The hepatic 
histological changes reported in TS patients vary and 
include minimal abnormalities, steatosis, steatohepatitis, 
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What this study adds?
Elevated liver function tests (LFTs) are common in adult patients with Turner syndrome (TS). Potential causes and mechanisms suggested 
in the literature are not clear, and may include autoimmunity, venous malformations, obesity and sex hormones replacement therapy 
(HRT). 
Elevated LFTs are common in children and adolescents with TS. Obesity and HRT do not increase the risk of elevated LFTs.
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biliary involvement, nodular regenerative hyperplasia and 
even cirrhosis (5,6,7,8,9,10,11,12,13,14,15,16,17,18,19). 
Potential causes and mechanisms are not clear and may 
include autoimmune processes, venous malformations, 
obesity and sex hormone replacement therapy (HRT) 
(5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20). However, 
some basic and animal studies point to the crucial 
a role of estrogen deficiency or estrogen receptor 
malfunction in the development of liver impairment 
(21,22,23,24,25,26,27). 
The aims of this study were to investigate the prevalence 
of abnormal LFTs in children and adolescents with TS; to 
analyse LFTs changes and their clinical significance over 
several years of observation; to evaluate the potential 
impact of increased body mass index (BMI) and sex HRT 
on LFTs.
Methods
The analysis included 100 girls with TS, aged 4-16, all of 
whom were being treated with human recombinant growth 
hormone. 44 patients were on HRT-estrogen and estrogen/
progestin patches. Patients were treated with daily injections 
of human rekombinant growth hormone, dose 0.33-0.47 
mg/kg/week. It was a retrospective analysis plus prospective 
follow-up period. Blood was collected in the fasting state, 
in the morning (7.00-9.00), during routine examinations 
performed in patients with TS.
The activity of aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) was measured in fresh 
serum samples using dry chemistry (VITROS® 5.1 FS, Ortho 
Clinical Diagnostics). 
Body height and weight were measured to the nearest 0.1 cm 
and 0.1 kg, respectively, using a stadiometer (Harpenden, 
UK) and a balanced scale (SECA).
Statistical Analysis
To compare the two sets of data, Student’s t-test or two-
sided Mann-Whitney U test were used. For a correlation 
analysis, the correlation coefficient (R) and regression 
analysis were used. Odds ratio (OR) was calculated using 
logistic regression analysis. A probability value of less than 
0.05 was accepted to be statistically significant
Ethics
The investigation was conducted according to the principles 
expressed in the Declaration of Helsinki. The participants 
and/or their parents signed informed consent. The study 
has been approved by the Jagiellonian University Bioethical 
Committee (decision number: KBET/102/B/2012); 
Results
The longitudinal study included 81 patients (mean follow-up 
period: 4.31 years, SD: 0.82). Mean BMI-standard deviation 
(SD) score (SDS) was 0.63 (SD: 1.53).
In the whole group of patients 17 were diagnosed with 
obesity (9 without HRT and 8 with HRT).
Elevated LFTs were found in 34 patients 34% [in 18 (32%) 
without HRT vs in 16 (36%) on HRT]. Increased AST activity 
was present in 10 (18%) without HRT; in 5 (11%) on HRT), 
and elevation of ALT [in 9 (16%) without HRT and in 11 
(25%) on HRT]. The mean values of AST in both groups 
(without HRT and with HRT) were 42.7 IU/L and 44.2 IU/L 
p=0.8, and the mean value of ALT were 27.5 IU/L and 29.9 
IU/L, p=0.14 respectively.
The mean values of AST in patients with obesity and non 
obese were 47.5 IU/L and 42.5 IU/L, p=0.8. The mean 
values of ALT in patients with obesity and non obese were 
35.6 IU/L and 27 IU/L, p=0.037.
The relative risk of increased LFTs activity was not higher in 
obese vs normal weight [OR: 0.2; 95% confidence interval 
(CI): 0.1-0.36, p=0.38 vs OR: 0.16; 95% CI: 0.08-0.3, 
p=0.1]. HRT did not increase the risk of abnormal LFTs 
activity (OR: 0.8; 95% CI: 0.5-1.2, p=0.37 vs OR: 0.7; 95% 
CI: 0.4-1.1, p=0.27). During the follow-up period, no patient 
developed overt liver disease. There was no significant 
increase nor decrease of the abnormal LFTs frequency in 
the subsequent years of follow up (p>0.05) (Figure 1).
Discussion
The reported frequency of elevated LFT activity in TS 
patients ranges from 20 to 80%, with the highest proportion 
in older patients (3,4,5,6,27,28). In a recent large study (842 
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Figure 1. Percentage of abnormal results of liver function 
tests during subsequent years of observation
AST: aspartate aminotransferase, ALT: alanine aminotransferase
pediatric patients) only 3.4% of 698 examined were found 
to have abnormal LFT results and in patients younger than 
10 years this was only found in five patients (29). Research 
carried out in older age groups indicates a much more 
frequent occurrence of abnormal LFTs. In the study of El-
Mansoury et al (27) 36% of 218 adult TS patients presented 
with abnormal levels of one or more liver enzymes at the 
beginning, and subsequently 23% more developed abnormal 
LFTs during a 5-year follow-up. In our study, we found a 
similar proportion of young TS patients with elevated LFTs 
at the beginning of the study (34%), but we did not observe 
any progression during the follow-up period. Although liver 
disease in patients with TS is generally more common than 
in the general population, so far no direct correlation has 
been found between the development of liver disease and 
the occurrence of abnormal LFTs in the preceding period. In 
most published studies LFTs did not progress to overt liver 
disease (1,17,18,19). Also, little is known about the factors 
predisposing to abnormal LFTs. The literature suggests the 
possible participation of obesity and HRT by analogy to the 
results of research conducted in various groups of patients 
(4). As women with TS have short stature and abnormal 
body proportions, they are more likely to be overweight and 
obese (4,17,18,19,30). In our present study, no relationship 
was found between obesity and LFTs. The relative risk of 
the development of LFTs was comparable in patients with 
obesity and normal BMI-SDS. This finding is in accordance 
with some earlier studies in this field, which confirmed 
obesity as a frequent finding in TS patients, but without 
correlation to liver impairment (5,27,31). Another potential 
factor widely considered in older publications as a cause 
of hepatotoxicity is estrogen replacement therapy (32,33). 
Estrogen receptors are expressed in the liver and estrogens 
probably play an important role in hepatic lipid homeostasis 
(34,35). Despite many studies performed in this field, the 
causative role of estrogens is not well established. Some 
reports suggest that estrogen replacement therapy in TS 
patients can cause deterioration of liver function and in 
some patients discontinuation of therapy was followed 
by a decrease in enzyme levels (36). In contrast, some 
more recent studies point to a potential role of estrogen 
replacement as a favourable factor improving liver function 
(21). Although some studies reported alterations in LFTs 
in TS patients treated with estrogens, these alterations 
did not improve with the discontinuation of replacement 
therapy (13,20). More recent studies also found elevated 
LFTs in young patients before HRT, and some showed a 
beneficial impact of estrogen replacement (4,28,31). In our 
study, sex HRT did not increase the risk of elevated ALT and 
AST. As we examined a group of pediatric TS patients, it 
can be difficult to compare our results with studies based 
on results of adult TS patients. More recent observational 
studies, conducted in post-menopausal women without HRT 
revealed an increased risk of liver steatosis, in comparison 
to pre-menopausal women (21,37,38). For this reason, the 
importance of estrogen in liver function has become the 
subject of many experimental studies. A number of basic 
and animal studies have revealed a crucial role of estrogens 
and estrogen receptor deficiency in the pathogenesis of liver 
dysfunction. Estrogens can mediate their biologic effects 
in the liver through a number of mechanisms. The classic 
mechanism involves its binding to the steroid nuclear 
hormone receptors, α or β. Both have the classic features 
of steroid hormone receptors (39). Estrogens can also alter 
cell signaling via estrogen receptor α or β, localized in 
the cell membrane. In addition to membrane localized α 
and β receptors, estrogens can signal through another cell 
surface receptor, the G-protein coupled estrogen receptor 
(GPER, also called Gpr30) which is expressed in multiple 
tissues, including liver (40). It has been shown recently 
that the loss of receptor α in the liver is associated with 
hepatic steatosis and inflammation, and its gene expression 
is lower in patients with non-alcoholic steatohepatitis (41). 
Zhu et al (22,23) reported that estrogen treatment may 
reverse aspects of pathway-selective insulin resistance 
by promoting insulin action on glucose metabolism but 
limiting hepatic lipid and diacylglycerol deposition. Estrogen 
treatment reduces liver fat storage on several levels, mainly 
by blocking insulin signaling to liver acetyl-CoA carboxylase 
and reducing hepatic apoB100 and phospholipid transfer 
protein. This protective effect of estrogen treatment 
requires intact hepatic estrogen signaling through estrogen 
receptor α. By contrast, hepatic estrogen signaling may not 
be required for the effects of estrogen treatment on body 
weight and adiposity (22,23). Moreover, Kao et al (42) found 
that estrogen receptor α could be an important mediator 
of liver regeneration. What is more, it has been shown 
that estrogen receptor β agonist might provide therapeutic 
benefits in liver steato-hepatititis by directly modulating 
the bile acid receptors in the liver, which have important 
functions in the liver, and indirectly, by inhibiting adiposity 
(43). The mechanisms by which estrogen signaling protects 
against hepatic steatosis also include reductions in de 
novo lipogenesis, as reported by Gao et al (25). These 
mechanisms may be helpful for understanding mechanisms 
of liver impairment in TS patients and the favourable action 
of estrogen replacement.
Study Limitations
The main limitation is its retrospective character leading to 
a lack of long-term observation for the whole group. Due 
to different models (transdermal/oral) of HRT and various 
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estradiol doses, the effect of estrogens on LFTs could not be 
accurately analyzed.
Conclusion
Constantly elevated LFTs in TS are common in children 
and adolescents with TS. However the causes and clinical 
significance remain unclear. This study suggests that obesity 
and HRT do not increase the risk of elevated LFTs.
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